SCHEMBL1346500

SCHEMBL1346500

CCCCCSc1ccccc1N

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 4/20 0.53
TLR8 Q9NR97 1/20 0.49
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
POLB P06746 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MAPT P10636 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
APOBEC3G Q9HC16 1/20 0.46
GAA P10253 1/20 0.46
HTT P42858 1/20 0.46
CYSLTR2 Q9NS75 1/20 0.46
CYSLTR1 Q9Y271 1/20 0.46
HSD17B10 Q99714 1/20 0.45
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
EPHX2 P34913 1/20 0.43
SOAT1 P35610 5/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11524757 0.98 PTGS2 (0.54) PTGS2TLR8MEN1KMT2APOLB
SCHEMBL9176625 0.98 PTGS2 (0.54) PTGS2TLR8MEN1KMT2APOLB
SCHEMBL9171692 0.98 PTGS2 (0.54) PTGS2TLR8MEN1KMT2APOLB
SCHEMBL9177320 0.98 PTGS2 (0.54) PTGS2TLR8MEN1KMT2APOLB
SCHEMBL425178 0.94 TLR8 (0.54) PTGS2TLR8MEN1KMT2APOLB
SCHEMBL9696731 0.86 POLB (0.65) PTGS2TLR8MEN1KMT2APOLB
SCHEMBL3628525 0.85 MEN1 (0.54) PTGS2TLR8MEN1KMT2APOLB
SCHEMBL7960309 0.84 MEN1 (0.48) PTGS2TLR8MEN1KMT2APOLB
Hydrochloric Acid SCHEMBL16445779 0.83 MEN1 (0.52) PTGS2TLR8MEN1KMT2APOLB
SCHEMBL28126730 0.83 MEN1 (0.52) PTGS2TLR8MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE45670-E1 Aryl carbonyl derivatives as therapeutic agents NOVO NORDISK A/S (DK) 2015-09-15 US disclosed
EP-1531815-B1 GLUCOKINASE ACTIVATORS NOVO NORDISK AS (DK) 2014-09-24 EP disclosed
EP-2471533-A1 Aryl carbonyl derivatives as therapeutic agents Novo Nordisk A/S (DK) 2012-07-04 EP disclosed
US-20110301158-A1 ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS NOVO NORDISK A/S (DK) 2011-12-08 US disclosed
US-8063081-B2 N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-11-22 US disclosed
US-7897628-B2 {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-03-01 US disclosed
US-7541373-B2 Aryl carbonyl derivatives as therapeutic agents NOVO NORDISK A/S (DK) 2009-06-02 US disclosed
US-7384967-B2 Aryl carbonyl derivatives as therapeutic agents NOVO NORDISK A/S (DK) 2008-06-10 US disclosed
US-20080119454-A1 Aryl carbonyl derivatives as therapeutic agents NOVO NORDISK A/S (DK) 2008-05-22 US disclosed
US-20080119455-A1 Aryl carbonyl derivatives as therapeutic agents NOVO NORDISK A/S (DK) 2008-05-22 US disclosed
US-20060183783-A1 Aryl carbonyl derivatives as therapeutic agents VTV THERAPEUTICS LLC 2006-08-17 US disclosed
EP-1531815-A1 GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2005-05-25 EP disclosed
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents VTV THERAPEUTICS LLC 2004-06-24 US disclosed
WO-2004002481-A1 ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS NOVO NORDISK A/S (DK) 2004-01-08 WO disclosed
EP-0903341-A1 \"Novel ortho-mercaptoaniline compounds\ Akzo Nobel N.V. (NL) 1999-03-24 EP disclosed
US-4727154-A ACRYLATION 2-MERCAPTOPHENYLUREA HOECHST AKTIENGESELLSCHAFT 1988-02-23 US disclosed
US-3985894-A Method of controlling rice blast with N-(alkylthiophenyl)maleimides THE DOW CHEMICAL COMPANY (US) 1976-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301158-A1 ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS GCK, GCKR, PDK2 PTGS2 1222/4885TLR8 2365/4885MEN1 4426/4885
US-20080119455-A1 Aryl carbonyl derivatives as therapeutic agents GCK, GCKR, PDK2 PTGS2 1222/4885TLR8 2365/4885MEN1 4426/4885
US-20060183783-A1 Aryl carbonyl derivatives as therapeutic agents GCK, PDK3, PDK4 PTGS2 1171/4885TLR8 1873/4885MEN1 4547/4885
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents GCK, GCKR, PDK2 PTGS2 1222/4885TLR8 2365/4885MEN1 4426/4885
US-20080119454-A1 Aryl carbonyl derivatives as therapeutic agents GCK, GCKR, PDK2 PTGS2 1222/4885TLR8 2365/4885MEN1 4426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.